Pfizer’s FDA-approved Cibinqo (abrocitinib) is a medication used to treat moderate to severe atopic dermatitis in adults and teens over the age of 12. It works by blocking a specific protein in the immune system that contributes to inflammation. Cibinqo is given as a tablet that is taken orally. The dosing frequency and amount of medication will depend on the patient's condition and response to treatment.
However, as a healthcare provider, obtaining access to Cibinqo enrollment forms can be time-consuming and confusing. In this article, we will provide you with access to Cibinqo enrollment forms and introduce you to the Pfizer Dermatology Patient AccessTM Program – which provides a variety of HCP and patient resources to streamline the process of prescribing Cibinqo to treat patients.